Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Real-World Insights from a Propensity Score Weighted Retrospective Cohort Study

American Journal of Nephrology 2026 Open access

Read full text
Authors: William R. Marshall, Rajkumar Chinnadurai, Sharmilee Rengarajan, Aine Maire De Bhailis, Julie Gorton, Philip A. Kalra, Grahame Wood
DOI: 10.1159/000551244
Cited by: 0
References: 19

Abstract

INTRODUCTION: Tolvaptan slows disease progression of autosomal dominant polycystic kidney disease (ADPKD) in clinical trials, but real-world effectiveness remains uncertain. We evaluated the association between tolvaptan use and kidney function decline in a large tertiary-centre cohort. METHODS: This retrospective cohort study evaluated adults with ADPKD attending a specialist polycystic kidney disease clinic. Patients with

Fields of Study & Subjects

Genetic and Kidney Cyst Diseases Cystic Fibrosis Research Advances Chronic Kidney Disease and Diabetes

Publication details

Journal / source
American Journal of Nephrology
Pages
1–13
Publication date
27 February 2026
Language
EN